ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cromolyn

Also written as “Cromoglicate”, “Cromolyn Sodium (34.2 mg BID)” and “Cromolyn Sodium (17.1 mg BID)”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Adenocarcinoma of Lung · Psoriasis · Mastocytosis, led by 4 companies.

Drug pageCromolyn: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 10, 20158 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AZTherapies40 open or runningphase 3since Sep 10, 2015Sep 10, 2015none ahead
LEO Pharmaits history only20 open or runningphase 2since Jul 11, 2012Jul 11, 2012none ahead
Carcinexits history only11 open or runningphase 1since Jun 16, 2026Jun 16, 2026Jun 2027phase 1 · NCT07675876
PhenoNetits history only11 open or runningphase 2since Aug 19, 2025Aug 19, 2025Mar 2027phase 2 · NCT07142291

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AZTherapies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2015First study: phase 3 study in Alzheimer DiseaseFirst studyNCT02547818 · 620 enrolled · United States, Australia, Bulgaria and more
  2. Jun 26, 2017Phase 2 study in Ischemic StrokeNCT03202147
  3. Jun 3, 2020Phase 2 study in Amyotrophic Lateral SclerosisNCT04428775 · 12 enrolled · United States
  4. Sep 17, 2020Phase 1 study in Alzheimer DiseaseNCT04570644 · 56 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 AZTherapies leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04570644Alzheimer Disease · United States1CompletedJan 18, 202156
NCT04428775Amyotrophic Lateral Sclerosis · United States2TerminatedOct 1, 202112
NCT03202147Ischemic Stroke2WithdrawnDec 20240
NCT02547818Alzheimer Disease · United States, Australia, Bulgaria and more3CompletedNov 13, 2020620

How it is read

Names in the registry

  • “Cromoglicate”, 2 entries
  • “Cromolyn Sodium (34.2 mg BID)”, 1 entry
  • “Cromolyn Sodium (17.1 mg BID)”, 1 entry
  • “Cromolyn Sodium”, 1 entry
  • “ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.